المصدر: A Phase Ib/II, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antineoplastic Activity of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

المؤلفون: Puyuan Xing, Qian Zhao, Li Zhang, Hanping Wang, Dingzhi Huang, Pei Hu, Yinghui Sun, Yuankai Shi

المصدر: BMC Medicine, Vol 20, Iss 1, Pp 1-15 (2022)

مصطلحات موضوعية: Non-small cell lung cancer, Anaplastic lymphoma kinase, Tyrosine kinase inhibitor, Conteltinib, CT-707, Phase 1 study, Medicine

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1741-7015

URL الوصول: https://doaj.org/article/64d5e5dcceb64e9da3e07fa212a806ff

المصدر: Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
Liang C, Zhang N, Tan Q, Liu S, Luo R, Wang Y, Shi Y, Han X. CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK. Curr Cancer Drug Targets. 2019;19(8):655-665. doi: 10.2174/1568009618666181031152140.